As the project partner, BLA congratulates Hangzhou Hanx Biopharmaceuticals on receiving IND may proceed letter for HX009 project
As the project partner, BLA congratulates Hangzhou Hanx Biopharmaceuticals on receiving IND may proc...
US FDA IND Application Strategy & Execution
Submitting an IND application to the US FDA is a significant step in the development of a new drug o...
As the project partner, BLA congratulates Deka Bioscienceson receiving IND may proceed letter for DK210 (EGFR) project
As the project partner, BLA congratulates Deka Bioscienceson receiving IND may proceed letter for DK...
As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520 project
As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520...
As the project partner, BLA congratulates Hangzhou Sumgen Biotech on receiving IND may proceed letter for SG1906 project
As the project partner, BLA congratulates Hangzhou Sumgen Biotech on receiving IND may proceed lette...
As the project partner, BLA Regulatory congratulates NKGen Biotech on receiving IND may proceed letter for allogeneic SNK02 project
As the project partner, BLA Regulatory congratulates NKGen Biotech on receiving IND may proceed lett...
BLA Regulatory Joins Maryland Trade Mission at BioJapan 2022 in Yokohama, Japan between 12-14 Oct.
BLA Regulatory Joins Maryland Trade Mission at BioJapan 2022 in Yokohama, Japan between 12-14 Oct. ...
Present at the 3rd Quality Science of Biologics Summit, 12-13 Aug. 2022, Beijing, China
Present at the 3rd Quality Science of Biologics Summit, 12-13 Aug. 2022, Beijing, China Gaithersb...
As the project partner, BLA Regulatory congratulates ImmuneOnco for receiving Fast Track designation from the FDA to IMM2902 for the treatment of HER-2+ breast cancer patients
As the project partner, BLA Regulatory congratulates ImmuneOnco for receiving Fast Track designation...